Peptides Vietnam LogoPeptides Vietnam
EN/VI
Molecule MechanicsNov 2026

Kybella: How the Fat-Dissolving Injection Works

Kybella works by destroying cell membranes in fat under the chin, so the cells burst. Its active ingredient is deoxycholic acid, a bile acid your body also makes to help absorb fats. It is a US prescription drug, approved only to improve the look of moderate to severe fullness from fat under the chin in adults.

That raises two puzzles. How does a molecule from digestion end up as a fat treatment, and why do its warnings mention a smile? This page follows the label, a small human tissue study, the 2004 lab work that led to the drug, its two main trials, and its status on 21 November 2026.

On this page

Key facts

What it is: Deoxycholic acid, a small bile acid molecule. The FDA said it is identical to the one the body makes.

How it works: The label says it physically destroys the cell membrane, so the cell bursts.

Approved use: Moderate to severe fullness from fat under the chin, in adults only. Not approved anywhere else on the body.

Main trials: Two matching placebo trials with 1,022 adults. About two in three on Kybella improved by at least one grade on both ratings.

Status on 21 November 2026: A US prescription drug from AbbVie, with a label last updated in September 2026.

Sources: Kybella label via openFDA; FDA news release, 29 April 2015 (archived); Drugs@FDA deoxycholic acid records via openFDA

What is Kybella?

Kybella is the brand name for deoxycholic acid, sold as a prescription drug in the US. The label calls it a cytolytic agent, meaning a drug that breaks cells open. When the FDA approved it on 29 April 2015, it said Kybella is identical to the deoxycholic acid the body makes.

Not a peptide. Deoxycholic acid has the formula C24H40O4 and a molecular weight of 392.57. It is a bile acid, not a chain of amino acids, so it is neither a peptide nor a protein.

Who made it. Its development code was ATX-101. The FDA named Kythera Biopharmaceuticals of Westlake Village, California, as the maker in 2015. Today the label lists AbbVie as the distributor, and Drugs@FDA lists AbbVie as the sponsor. A 2016 overview says it was approved in 2015 as Kybella in the US and as Belkyra in Canada.

Sources: Kybella label via openFDA; FDA news release, 29 April 2015 (archived); Drugs@FDA deoxycholic acid records via openFDA; ATX-101 program overview, 2016

Where does deoxycholic acid come from?

Deoxycholic acid comes from digestion. The Kybella label calls it a natural bile component and a product of cholesterol metabolism. Most of it stays in a loop between the gut and the liver, called the enterohepatic circulation. The FDA said its normal job is to help the body absorb fats.

Gut bacteria do part of the work. A recent review explains that the liver makes a related bile acid, cholic acid. A small group of gut bacteria then turn it into deoxycholic acid, which the body takes back up. So the body makes it with help from its microbes.

After treatment. The label reports that blood levels of deoxycholic acid were back in the body's natural range within 24 hours. The drug joins the body's own bile acid pool and leaves the same way.

Sources: Kybella label via openFDA; FDA news release, 29 April 2015 (archived); Review of bile acids, Current Issues in Molecular Biology

How does Kybella work?

Kybella works by breaking cell membranes. Section 12.1 of the label says that in fat under the chin, it physically destroys the cell membrane, causing lysis. Lysis means the cell bursts.

Described as a detergent. A 2010 lab and animal paper describes deoxycholate as a detergent that quickly disrupts cell membranes. The label uses a related word for the drug: cytolytic, or cell breaking.

Other cells can be harmed too. The FDA said in 2015 that the drug destroys fat cells when it is in fat under the chin. But it can also destroy other cells, such as skin cells, if it ends up in the skin by mistake.

Sources: Kybella label via openFDA; Lab and animal study of deoxycholate, 2010; FDA news release, 29 April 2015 (archived)

What happens to the fat after the cells burst?

In one small human study, the treated fat went from burst cells to shrunken fat lobules over four weeks. Fourteen adults had belly fat treated before a planned tummy tuck, as research and not the approved use. Tissue samples from set days showed what changed.

  • Day 1: burst fat cells, injury to small blood vessels, and inflammation.
  • Day 7: immune cells called macrophages, loaded with fat, gathered in the walls between fat lobules.
  • Day 28: the inflammation had largely settled. The walls were thicker, new blood vessels had formed, and the fat lobules had shrunk.

Keep the limits in view. It was an open-label Phase 1 study of 14 people. Some of the tested concentrations were higher than the marketed one, and the authors worked for the drug's maker.

Sources: Human tissue study, 14 adults

Why does Kybella mostly hit fat?

Nobody has proven why in people, but one study offers a possible answer. In lab dishes, deoxycholate burst every cell type the researchers tested. In lab and animal work, albumin and other protein-rich tissue blunted it. The authors suggested that fat holds few of these proteins, so it may not be able to soak up the detergent.

How selective is it? A 2022 paper on CBL-514, a rival drug, calls deoxycholic acid relatively nonselective. It says the drug mainly hits fat cells but has some ability to burst muscle and nearby tissue. Caliway, the maker of CBL-514, funded that paper, and its authors include Caliway employees, so read it as a competitor's view.

Sources: Lab and animal study of deoxycholate, 2010; CBL-514 Phase 2a paper, 2022

How did a bile acid become a fat treatment?

It started as a hidden helper in another formula. In 2004, researchers at UCLA tested a popular fat-dissolving mix based on phosphatidylcholine. They used cell cultures and pig skin, not people. Their findings suggested that sodium deoxycholate, a bile salt added to help the mix dissolve, was the main thing bursting the cells.

Kybella's active ingredient is that same bile acid, now as a drug on its own. A 2016 overview says the ATX-101 program ran 18 Phase 1 to 3 studies, including 4 large Phase 3 trials: 2 in Europe and 2 in the US and Canada.

Sources: UCLA lab study, 2004; ATX-101 program overview, 2016

What did the Kybella trials find?

In the two main trials, about two in three people on Kybella improved by at least one grade, against about one in five on placebo. Both trials were randomized, double-blind and placebo-controlled, with the same design. The label calls them Trials 1 and 2; the papers call them REFINE-1 and REFINE-2. Together they enrolled 1,022 adults in the US and Canada, starting in early 2012.

Who took part. Healthy adults aged 19 to 65, with an average age of 49. Most were women (85%), and 87% were White, which limits how far the results reach.

What was measured. Chin fullness was scored on a scale from 0 (none) to 4 (extreme). A clinician and the patient each gave a score, 12 weeks after the final treatment. To count, a person had to improve on both scores at once.

Share of people who improved, Kybella against placebo, from the Kybella label.
ResultTrial 1 (REFINE-1)Trial 2 (REFINE-2)
At least 1 grade better on both ratings70.0% vs 18.6%66.5% vs 22.2%
At least 2 grades better on both ratings13.4% vs under 0.1%18.6% vs 3.0%

The smaller number. A two-grade change was far less common than a one-grade change. Only 13.4% and 18.6% of people on Kybella reached it.

MRI check. In a subset of 449 people scanned by MRI, 43% on Kybella lost at least 10% of their chin fat volume, against 5% on placebo. Put the other way, most of the Kybella group in that subset did not reach the 10% mark. The REFINE-1 paper alone reports 46.3% against 5.3%.

Not everyone finished. Only 59% of people in the trials received every treatment session the trial plan allowed. The REFINE-2 authors note that follow-up stopped at 44 weeks.

Two earlier Phase 3 trials in Europe, with 363 and 360 patients, also found more responders on the drug than on placebo. All of these are group results from company-sponsored trials, not a promise for any one person.

Sources: Kybella label via openFDA; ClinicalTrials.gov, NCT01542034; REFINE-1 paper, 2016; REFINE-2 paper, 2016; European Phase 3 trial, 363 patients; European Phase 3 trial, 360 patients

Do Kybella results last?

For people who responded, most results held for three years in one follow-up study. It tracked 224 people from the REFINE trials who had already improved: 113 on Kybella and 111 on placebo. At year 3, 82.4% of the Kybella group still held at least a one-grade gain on the clinician scale, against 65.0% of placebo responders.

That study followed responders only, so it does not describe everyone who was treated. Our sources hold no data past three years. One author worked for AbbVie.

Sources: Three-year follow-up of REFINE responders

What are the side effects of Kybella?

Almost everyone in the trials had some reaction where they were treated, and the label adds two named warnings. The table pools both trials: 513 people on Kybella and 506 on placebo.

Side effects in the two main trials, from Table 1 of the Kybella label.
Side effectKybellaPlacebo
Any reaction at the treatment area96%81%
Swelling87%43%
Bruising72%70%
Pain70%32%
Numbness66%6%
Nerve injury near the jaw4%under 1%
Trouble swallowing2%under 1%
  • Why a smile: the first warning is injury to the marginal mandibular nerve near the jaw. It showed up as an uneven smile or facial muscle weakness. In the trials every case cleared without extra treatment, from 1 to 298 days, with a median of 44.
  • Trouble swallowing: it came with pain, swelling and hardening under the chin. Trial cases cleared without extra treatment, with a median of 3 days and a range of 1 to 81. People with past swallowing problems were kept out of the trials.
  • Effects that lingered: numbness lasted more than 30 days in 42% of the Kybella group, swelling in 20%, pain in 16% and hardening in 13%.
  • Problems at the treatment area: hair loss that may persist, ulcers, tissue death, infection, and lumps. Some lumps may not go away and may need medical care.
  • Use outside the chin: the label warns of serious reactions after unapproved use, such as blurred or reduced vision near the eyes, and muscle or nerve injury. This section was updated in September 2026.

The most common side effects, each in over 20% of people, were swelling, bruising, pain, numbness, redness and hardening where treated. Whether these risks are worth it for one person is a call for them and their clinician.

Sources: Kybella label via openFDA; REFINE-1 paper, 2016

Is Kybella FDA approved?

Yes, for one use. On 21 November 2026, Drugs@FDA listed Kybella (NDA 206333, AbbVie) as a prescription drug, first approved on 29 April 2015 as a new molecular entity. Its label is approved to improve the look of moderate to severe convexity or fullness from submental fat in adults.

  • Not for other areas: it is not approved for fat outside the area under the chin, and the label says such use is not recommended.
  • Not for young people: safety and effectiveness are not established in children, and it is not recommended for children or adolescents.
  • Latest label: effective 11 September 2026, with changes to warning sections 5.3 and 5.5.
  • A generic: Drugs@FDA also lists ANDA 212296, a deoxycholic acid product from Wilshire Pharms approved on 2 April 2021. We did not check whether it is sold.

We did not re-check its status outside the US. How we read FDA records before stating an approval is set out in our medical review policy.

Sources: Drugs@FDA deoxycholic acid records via openFDA; Kybella label via openFDA

Is there a different way to clear fat cells?

One candidate under study is CBL-514, and it is still investigational. When we checked ClinicalTrials.gov on 20 November 2026, two Phase 3 trials of it were listed as recruiting in the US and Canada. The records we checked showed no approval, and its maker still calls it a drug candidate.

How it is meant to differ from Kybella, with its trial numbers and safety record set side by side, is covered on our CBL-514 explainer. We found no head-to-head human study of the two, so neither page calls one better or safer.

Sources: ClinicalTrials.gov, SUPREME-02; Caliway release, November 2026

What else do people ask about Kybella?

What is Kybella?+

Kybella is a US prescription drug whose active ingredient is deoxycholic acid, a bile acid. Its FDA label calls it a cytolytic drug, one that breaks cells open. It is approved only to improve the look of moderate to severe fullness from fat under the chin (submental fat) in adults. The FDA approved it on 29 April 2015.

Is Kybella a peptide?+

No. Deoxycholic acid is a small molecule made of carbon, hydrogen and oxygen (C24H40O4), with a molecular weight of 392.57. It is a bile acid, not a chain of amino acids, so it is neither a peptide nor a protein.

How does Kybella work?+

Section 12.1 of the label says that in fat under the chin, Kybella physically destroys the cell membrane, which causes the cell to burst (lysis). Researchers compare deoxycholate to a detergent that breaks up membranes. In a small tissue study of belly fat, fat-loaded immune cells appeared by day 7, and the fat lobules had shrunk by day 28.

What is the downside of Kybella?+

Reactions at the treatment area were close to universal in the trials: 96% on Kybella against 81% on placebo. Numbness lasted more than 30 days in 42% of people on Kybella. The label warns about nerve injury near the jaw that can cause an uneven smile, trouble swallowing, hair loss that may persist, ulcers, tissue death, infection and lumps that may not go away.

Is Kybella permanent?+

There is no lifetime data in our sources. One follow-up study tracked 224 trial patients who had already responded. At year 3, 82.4% of the Kybella group still held at least a 1-grade improvement, against 65.0% of placebo responders. It followed responders only, so it says nothing about people who did not respond.

Is Kybella painful?+

Pain at the treatment area was reported by 70% of people on Kybella in the two main trials, against 32% on placebo. Pain lasted more than 30 days in 16% of the Kybella group. How it feels for any one person is a question for the clinician who would treat them.

Can Kybella be used on other parts of the body?+

Not under its approval. The label says Kybella is not approved for fat outside the area under the chin, and that such use is not recommended. It also warns of serious reactions after unapproved use elsewhere, such as blurred or reduced vision when used around the eyes.

Is there a generic Kybella?+

Drugs@FDA lists one generic deoxycholic acid product, ANDA 212296 from Wilshire Pharms, approved on 2 April 2021 and listed as a prescription drug. We did not check whether it is actually sold. A listing shows approval, not stock.

Is Kybella the same as a fat-dissolving "lipo" shot?+

No. Kybella is one FDA-approved drug for one area. Its link to older fat-dissolving formulas is historical: in 2004, UCLA researchers found that the bile salt added to a phosphatidylcholine formula seemed to be the part bursting cells. The active ingredient in Kybella is deoxycholic acid itself.

Can teenagers use Kybella?+

Its safety and effectiveness have not been established in children, and the label says it is not recommended for children or adolescents. The trials enrolled healthy adults aged 19 to 65.

Sources: Kybella label via openFDA; Drugs@FDA deoxycholic acid records via openFDA; FDA news release, 29 April 2015 (archived); Lab and animal study of deoxycholate, 2010; Human tissue study, 14 adults; Three-year follow-up of REFINE responders; UCLA lab study, 2004

What did we learn about Kybella?

In short, Kybella turns a digestive bile acid into a drug that pops fat cell membranes under the chin. It is approved for that one area in adults. In its trials, the best-known risk was a nerve injury near the jaw that caused an uneven smile, and every trial case cleared.

Molecule Mechanics pages explain how one molecule works, with every source listed, and never recommend a treatment. Other pages in the series cover how tirzepatide works and our page on Dercum's disease.

If a fact here looks wrong, our corrections policy shows how to tell us.

Sources: Kybella label via openFDA

For learning only, and not medical advice. Everything above comes from the Kybella label, FDA records and published research on deoxycholic acid. It describes the drug and does not tell anyone whether to use it.

Sources

  1. 1.KYBELLA (deoxycholic acid) FDA prescribing information and patient leaflet, label effective 11 September 2026, set id fe431ed4, read through openFDA on 21 November 2026. Parts used: 1 (approved use, adults only); 5.1 to 5.5 (nerve injury near the jaw, trouble swallowing, treatment area problems including hair loss, ulcers, tissue death and lumps, and reactions after use outside the chin); 6 (Table 1 side effects and how long they lasted); 8.4 (children); 11 (cytolytic agent, formula C24H40O4, 392.57 g/mol); 12.1 (physically destroys the cell membrane, causing lysis); 12.3 (natural bile component, enterohepatic loop, back to the natural range within 24 hours); 14 (Trials 1 and 2: design, ages 19 to 65, mean age 49, 85% women, the 1-grade and 2-grade composite results, the MRI subset of 449, the 59% who received every session).
  2. 2.Drugs@FDA through openFDA, every deoxycholic acid application, read 21 November 2026: NDA 206333 (KYBELLA, AbbVie), original approval 29 April 2015, Type 1 new molecular entity, Prescription, labeling supplements approved 11 September 2026; ANDA 212296 (deoxycholic acid, Wilshire Pharms), approved 2 April 2021, Prescription.
  3. 3.US Food and Drug Administration, news release, 29 April 2015, archived copy: FDA approves Kybella; identical to the deoxycholic acid made in the body, which helps the body absorb fats; can also destroy other cells such as skin cells if placed in the skin by mistake; two trials, 1,022 adults; not approved outside the area under the chin; made by Kythera Biopharmaceuticals, Westlake Village, California.
  4. 4.Review of secondary bile acids, Current Issues in Molecular Biology (MDPI), doi 10.3390/cimb48100974, full text via Europe PMC: the liver makes cholic acid, and a limited group of gut bacteria turn it into deoxycholic acid, which is then reabsorbed. A review, not primary data.
  5. 5.Thomas WW and colleagues, deoxycholate study, 2010, PMID 20482723, abstract via PubMed: describes the bile acid as a detergent that rapidly disrupts cell membranes; in lab dishes it caused lysis of all cell types tested; albumin and protein-rich tissue blunted it; fat being low in these proteins is offered as a possible explanation.
  6. 6.Rotunda AM and colleagues, UCLA, 2004, PMID 15209790, abstract via PubMed: a phosphatidylcholine fat-dissolving formula tested on cell cultures and pig skin; the findings suggest sodium deoxycholate is the major active component responsible for cell lysis.
  7. 7.Phase 1 open-label tissue study of ATX-101 in 14 adults, abdominal fat treated before planned abdominoplasty, PMID 30883481, abstract via PubMed: day 1 fat cell bursting, vessel injury and inflammation; day 7 lipid-laden macrophages; day 28 inflammation largely resolved, thicker septa, new vessels, shrunken fat lobules. Authors are company employees.
  8. 8.Overview of the ATX-101 program, 2016, PMID 27787266, abstract via PubMed: code name ATX-101; approved in 2015 as Kybella in the US and Belkyra in Canada; 18 Phase 1 to 3 studies including 4 large Phase 3 trials. Authors include former Allergan employees.
  9. 9.ClinicalTrials.gov records NCT01542034 and NCT01546142 (the two US and Canada Phase 3 trials), read 20 November 2026: started February and March 2012, primary completion May 2013, 506 and 516 enrolled.
  10. 10.Jones DH and colleagues, REFINE-1, Dermatologic Surgery 2016, PMID 26673433: 256 on ATX-101 and 250 on placebo; MRI responders 46.3% against 5.3%; marginal mandibular nerve paresis in 4.3% on ATX-101. Company sponsored.
  11. 11.Humphrey S and colleagues, REFINE-2, 2016, PMID 27430612: 258 people per group; the authors list follow-up limited to 44 weeks as a limitation. Company sponsored.
  12. 12.Long-term follow-up of REFINE responders, PMID 33617632, registry NCT02163902: 224 people who had responded (113 on the drug, 111 on placebo); at year 3, 82.4% against 65.0% kept at least a 1-grade improvement on the clinician scale (P = 0.03). One author is an AbbVie employee.
  13. 13.European Phase 3 trial of ATX-101, 363 patients with moderate or severe chin fat, randomized against placebo, PMID 24147933.
  14. 14.Second European Phase 3 trial of ATX-101, 360 patients, randomized against placebo, PMID 24605812.
  15. 15.Goodman GJ and colleagues, CBL-514 Phase 2a paper, 2022, PMC9384315, full text via Europe PMC: calls deoxycholic acid relatively nonselective, with some ability to lyse muscle; reports CBL-514 cell and animal findings citing unpublished company reports. Caliway funded the study; authors include Caliway employees.
  16. 16.Caliway Biopharmaceuticals, news release dated 6 November 2026 (syndicated 19 November 2026): CBL-514 is a drug candidate designed to selectively induce fat cell apoptosis. Company wording.
  17. 17.ClinicalTrials.gov, SUPREME-02 (NCT07526974) and SUPREME-01 (NCT07140939), read 20 November 2026: both Phase 3, recruiting, about 320 planned participants each, United States and Canada.